Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes

Heller, Simon; Raposo, João Filipe; Tofé, Santiago; Hanif, Wasim; Schroner, Z; Down, Su; Blevins, Thomas

doi:10.2337/cd22-0016

Cited by 3 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past, the pricing of long acting analogs has limited their use in resource poor settings159; however, their inclusion in WHO’s list was a major step in improving their affordability 158. With the introduction of lower cost long acting insulin biosimilars, improved access to these worldwide in the future can be anticipated 160…”

Section: Management In Under-resourced Settingsmentioning

confidence: 99%

“…158 With the introduction of lower cost long acting insulin biosimilars, improved access to these worldwide in the future can be anticipated. 160 Making insulin available is not enough on its own to improve the prognosis for patients with diabetes in resource poor settings. 161 Improved healthcare infrastructure, better availability of diabetes supplies, and trained personnel are all critical to improving type 1 diabetes care in LMICs.…”

Section: Management In Under-resourced Settingsmentioning

confidence: 99%

See 1 more Smart Citation

New advances in type 1 diabetes

Subramanian,

Khan,

Hirsch

2024

BMJ

View full text Add to dashboard Cite

Type 1 diabetes is an autoimmune condition resulting in insulin deficiency and eventual loss of pancreatic β cell function requiring lifelong insulin therapy. Since the discovery of insulin more than 100 years ago, vast advances in treatments have improved care for many people with type 1 diabetes. Ongoing research on the genetics and immunology of type 1 diabetes and on interventions to modify disease course and preserve β cell function have expanded our broad understanding of this condition. Biomarkers of type 1 diabetes are detectable months to years before development of overt disease, and three stages of diabetes are now recognized. The advent of continuous glucose monitoring and the newer automated insulin delivery systems have changed the landscape of type 1 diabetes management and are associated with improved glycated hemoglobin and decreased hypoglycemia. Adjunctive therapies such as sodium glucose cotransporter-1 inhibitors and glucagon-like peptide 1 receptor agonists may find use in management in the future. Despite these rapid advances in the field, people living in under-resourced parts of the world struggle to obtain necessities such as insulin, syringes, and blood glucose monitoring essential for managing this condition. This review covers recent developments in diagnosis and treatment and future directions in the broad field of type 1 diabetes.

show abstract

Section: Management In Under-resourced Settingsmentioning

confidence: 99%

Section: Management In Under-resourced Settingsmentioning

confidence: 99%

New advances in type 1 diabetes

Subramanian,

Khan,

Hirsch

2024

BMJ

View full text Add to dashboard Cite

show abstract

“…Interchangeability at pharmacies can simplify the use of biosimilar insulin by streamlining the substitution process. Benefits include easier transition to a less expensive product, decreased time for medical provider approval, resulting in shorter waiting period at the pharmacy, and a smoother shift to lower-cost insulin, ultimately reducing healthcare system expenses [ 21 ].…”

Section: Reviewmentioning

confidence: 99%

Insulin Access Enhancement in India: Expert Views on Integrating Interchangeable Biosimilar Insulin Glargine

Prasanna Kumar,

Chowdhury,

Bantwal

et al. 2024

Cureus

View full text Add to dashboard Cite

Achieving and maintaining optimal glycemic targets is the fundamental goal of the management of diabetes. However, failure of oral antidiabetic drugs (OADs) to sustain the targeted glycemic levels in individuals with progressing disease often requires initiation of insulin therapy. This article consolidates the expert opinions of 377 doctors who participated in 34 advisory board meetings held digitally (n=23) and in person (n=11) across India. The present report underscores the need for readily available alternatives, such as biosimilar insulins, in the Indian healthcare market to make insulin accessible to every patient with diabetes. The introduction of biosimilar insulins in the Indian healthcare market is the key to making insulin accessible to every patient with diabetes. Biosimilars are biologic products that closely resemble reference/originator biologics and demonstrate no clinically meaningful differences in safety and effectiveness. The concept of interchangeability serves as a pivotal differentiator for biosimilars, underlining their reliability and safety, and plays a significant role in their broader acceptance and integration into healthcare systems. The 'interchangeability' designation by the United States Food and Drug Administration (USFDA) elevates the biosimilar concept, promoting faster and broader adoption of insulin biosimilars, especially benefiting patients prone to non-adherence to insulin therapy. Healthcare providers are encouraged to consider the option of initiating or transitioning to biosimilar insulin glargine to address the insulin accessibility challenges.

show abstract